Does DARATUMUMAB Cause Second primary malignancy? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Second primary malignancy have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.0% of all adverse event reports for DARATUMUMAB.
10
Reports of Second primary malignancy with DARATUMUMAB
0.0%
of all DARATUMUMAB reports
2
Deaths
3
Hospitalizations
How Dangerous Is Second primary malignancy From DARATUMUMAB?
Of the 10 reports, 2 (20.0%) resulted in death, 3 (30.0%) required hospitalization, and 2 (20.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DARATUMUMAB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does DARATUMUMAB Cause?
Plasma cell myeloma (2,980)
Infusion related reaction (2,557)
Off label use (2,494)
Pneumonia (1,450)
Neutropenia (1,351)
Drug ineffective (1,110)
Thrombocytopenia (1,089)
Death (1,088)
Pyrexia (1,032)
Dyspnoea (996)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which DARATUMUMAB Alternatives Have Lower Second primary malignancy Risk?
DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ
DARATUMUMAB vs DARBEPOETIN ALFA
DARATUMUMAB vs DARIDOREXANT
DARATUMUMAB vs DARIFENACIN HYDROBROMIDE
DARATUMUMAB vs DAROLUTAMIDE